Vertex to buy Crinetics for $10 billion to expand rare-disease business

Vertex to buy Crinetics for $10 billion to expand rare-disease business FILE PHOTO: A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston, Massachusetts, U. S. , October 23, 2019.

REUTERS/Brian Snyder/File Photo · Reuters Reuters Mon, July 6, 2026 at 10:21 PM GMT+2 1 min read VRTX CRNX July 6 (Reuters) - Vertex Pharmaceuticals will buy Crinetics Pharmaceuticals for a total equity ‌value of about $10 billion, the companies ‌said on Monday. Shares of Crinetics more than doubled in ​extended trading, while those of Vertex were marginally down. The acquisition gives Vertex access to Palsonify, which was approved by the U.

S. ‌Food and Drug ⁠Administration in September 2025 to treat adults with acromegaly, a rare ⁠hormonal disorder caused by excess growth hormone. The companies said the once-daily oral therapy ​has shown ​early commercial momentum ​since launch.

Crinetics' experimental drug, ‌atumelnant, is in late-stage development for congenital adrenal hyperplasia, or CAH, a rare genetic disorder affecting the adrenal glands. The companies said Palsonify and atumelnant could together generate more ‌than $5 billion in peak ​annual sales. Vertex expects ​the deal to ​add immediately to revenue growth ‌and become accretive to non-GAAP ​operating income ​in 2029.

Vertex will pay $85 per Crinetics share, the companies said, with the deal ​expected to ‌close in the third quarter of ​2026.